Venous and arterial thrombosis following administration of intravenous immunoglobulins

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 5, 2005, Pages 313-318

  Paran, Daphna ^a   Herishanu, Yair ^a   Elkayam, Ori ^a   Shopin, Ludmila ^a   Ben Ami, Ronen ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Adverse effects; Intravenous immunoglobulins; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; IMMUNOGLOBULIN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; IMMOBILIZATION; INCIDENCE; LUNG EMBOLISM; MALE; MORTALITY; MULTIPLE MYELOMA; OBESITY; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; VEIN THROMBOSIS; VENOUS STASIS;

EID: 22444443589     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000172694.85233.a8     Document Type: Review

References (41)

1. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000; 34:295-299.
2. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986; 2:217-218.
3. Zaidan R, Al MM, Wani BA, Shameena AR, Al Tahan AR, Daif AK, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003; 10:367-372.
4. Okuda D, Plaster M, Frey J, Sivakumar K. Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 2003; 60:1825-1826.
5. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60:1822-1824.
6. Brown HC, Ballas ZK. Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. J Allergy Clin Immunol 2003; 112:797-799.
7. Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003; 139:991-993.
8. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002; 22:1638-1641.
9. Byrne NP, Henry JC, Herrmann DN, Abdelhalim AN, Shrier DA, Francis CW, et al. Neuropathologic findings in a Guillain-Barre patient with strokes after IVIg therapy. Neurology 2002; 59:458-461.
10. Turner B, Wills AJ. Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2000; 68:790-791.
11. Chatot-Henry C, Smadja D, Mehdaoui H, Fournerie P, Drault JN, Brebion A, et al. Acute renal insufficiency and cerebral infarction during high-dose intravenous immunoglobulin therapy. Rev Med Interne 1998; 19:914-916.
12. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44:223-226.
13. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994; 44:1180-1181.
14. Durand JM, Lefevre P, Kaplanski G, Retornaz F, Cretel E, Soubeyrand J. Deleterious effects of intravenous immunoglobulin in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44:214-215.
15. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992; 42:257-258.
16. Steinberger B, Coleman TA. Multiple complications of IVIG therapy in a patient with Guillain-Barre syndrome [Letter]. Am J Hematol 2001; 67:59.
17. Stamboulis E, Theodorou V, Kilidireas K, Apostolou T. Acute myocardial infarction following intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy in association with a monoclonal immunoglobulin G paraprotein. Eur Neurol 2004; 51:51.
18. Struble EJ, Dice YG. Intravenous immune globulin (IVIG) precipitating acute myocardial infarction. J Miss State Med Assoc 2002; 43:11 5.
19. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000; 65:177-178.
20. Elkayam O, Paran D, Milo R, Davidovitz Y, Moznino-Sarafian D, Zeltser D, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000; 59:77-80.
21. Rosenbaum JT. Myocardial infarction as a complication of immunoglobulin therapy. Arthritis Rheum 1997; 40:1732-1733.
22. Fisman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997; 13:775-777.
23. Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulin [Letter]. Lancet 1986; 2:468.
24. Crouch ED, Watson LE. Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura - a case report and literature review. Angiology 2002; 53:113-117.
25. Ropper AH, Adelman L. Early Guillain-Barre syndrome without inflammation. Arch Neurol 1992; 49:979-981.
26. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50:172-175.
27. Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders - a prospective study. J Neurol 2003; 250:818-821.
28. Butler KS, Zeitlin DS. Pulmonary embolism associated with intravenous immunoglobulin therapy [Letter]. Ann Pharmacother 2003; 37:1530.
29. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D. Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 2001; 94: 187-188.
30. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000; 75:83-85.
31. Brannagan TH III, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47:674-677.
32. Evangelou N, Littlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003; 56:308-309.
33. Harkness KA, Goulding P. Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 2000; 14:662-663.
34. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997; 124:416-418.
35. 2002 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. Online: http://www.fda.gov/medwatch/SAFETY/2002/ safety02.htm [accessed 28 March 2005].
36. Product Approval Information -Licensing Action: Immune Globulin Intravenous (Human), 10% by Chromatography Process (Gamunex). Online: http://www.fda.gov/cber/products/igivbay082703.htm [accessed 28 March 2005].
37. Ben-Ami R, Barshtein G, Mardi T, Deutch V, Elkayam O, Yedgar S, et al. A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation. Am J Physiol Heart Circ Physiol 2003; 285:H2663-H2669.
38. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339:662-664.
39. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65:30-34.
40. Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol 1999; 41:153-158.
41. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin. Neurology 1996; 46:250-251.